10x Genomics Reports Third Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
10x Genomics (TXG) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
November 6, 2025 4:35 PM EST10x Genomics (NASDAQ: TXG) reported Q3 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $149 million versus the consensus estimate of $142.5 million.
GUIDANCE:
10x Genomics sees Q4 2025 revenue of $154-158 million, versus the... More
